Alnylam is the latest partner in the Medicines Manufacturing Innovation Centre’s third Grand Challenge project, which aims to revolutionise the manufacturing process for oligonucleotide therapies
The platform will provide a safe and nurturing space for women, and non-binary individuals
The start-up claims in clinical trials over 90 % achieved type 2 diabetes reversal and 92 % eliminated all diabetes medication within 90 days of joining the twin service
The aim is to first produce Covid-19 vaccines and then add more vaccines in the years to come
The company will use the capital for building its team, product development, marketing, and setting up in-school clinics to deliver connected health to one million families
The company claims to be a market leader in core orthopaedic and gynaecology segments like bone and joint disorders, pain management and, pregnancy and women’s nutrition
The first clinical trial is expected to commence in early 2022 both in Europe and the US
This one-of-a-kind innovation challenge is aimed at addressing the challenges faced by healthcare providers in digital technology adoption
The AI-infused solution enables radiologists by fast triaging abnormalities in X-ray, annotating and automatic report generation with significantly improved performance
The listings aim to address global health priorities, identifying the medicines that provide the greatest benefits, and which should be available and affordable for all
Subscribe To Our Newsletter & Stay Updated
